Low Blood Sugar Risk and Drug Interactions with Orforglipron

Release date: 2026-06-12 11:58:47     Recommended: 16

Low Blood Sugar Risk and Drug Interactions with Orforglipron

Patients using Orforglipron need to pay special attention to the risk of hypoglycemia (low blood sugar), especially when taking other medications that may lower blood glucose. Specifically, if you are using insulin or sulfonylureas (such as glimepiride, glipizide, etc.) to treat diabetes, combining them with Orforglipron significantly increases the likelihood of hypoglycemia. This is because Orforglipron itself has glucose-lowering and weight-loss effects, and the additive effect with the above medications may cause blood glucose to drop too low. Typical symptoms of hypoglycemia include: dizziness or lightheadedness, increased sweating, confusion or drowsiness, headache, blurred vision, slurred speech, tremors, rapid heartbeat, anxiety or irritability, mood swings, unusual hunger, general weakness, or restlessness. If any of these symptoms occur, check your blood glucose immediately and take appropriate action (such as eating fast-acting carbohydrates). To reduce risk, your doctor may adjust the dose of insulin or sulfonylureas before or during your treatment with Orforglipron. At your first visit, be sure to tell your doctor all glucose-lowering medications you are taking. Additionally, if you are taking oral contraceptives, Orforglipron may affect their absorption and effectiveness. Your doctor may recommend adding a barrier method of contraception for 30 days after starting Orforglipron and after each dose increase.

Pregnancy and Breastfeeding Considerations for Orforglipron

For women of childbearing age, if you become pregnant or plan to become pregnant while using Orforglipron, you must be aware of the potential risks of the medication to the fetus. Based on available information, Orforglipron may harm an unborn baby, so it is not recommended during pregnancy. If you discover that you are pregnant while taking this medication, tell your doctor immediately and discuss whether to continue treatment. Regarding breastfeeding, it is unknown whether Orforglipron passes into breast milk or affects the infant. Given the lack of safety data, breastfeeding is not recommended during treatment with Orforglipron. If you are currently breastfeeding or plan to breastfeed, talk with your doctor before starting the medication to discuss alternative weight management options or adjust your treatment plan. Your doctor will help you weigh the benefits and risks to make the best choice for you and your baby.

Special Precautions Before Surgery or Anesthesia

If you are scheduled to undergo any procedure requiring anesthesia or deep sedation (including surgery, gastrointestinal endoscopy, dental procedures, etc.), you must inform your medical team that you are taking Orforglipron. This is because GLP-1 medications (including Orforglipron) delay gastric emptying, meaning food and liquids stay in the stomach longer than usual. During a procedure, even if you have fasted as instructed, undigested contents may remain in the stomach. Under anesthesia or deep sedation, normal throat and cough reflexes are suppressed, which significantly increases the risk of regurgitation and aspiration of stomach contents into the lungs. Aspiration can lead to severe aspiration pneumonia, airway obstruction, or even acute respiratory distress syndrome, which can be life-threatening. Therefore, your anesthesiologist and surgeon need to know that you are using Orforglipron in advance to assess risks and develop a personalized anesthesia plan, such as adjusting the fasting period, using rapid sequence induction anesthesia, or recommending temporary discontinuation of the medication if necessary. The specific duration of withholding the medication should be determined by your doctor. Do not increase your surgical risk by forgetting to inform your team.